Welcome to Cato Research

Cato Research is a full-service contract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, and medical devices to the people who need them.

» Cato Research Overview | Contact Us

» Cato BioVentures

Announcements

  • Cato Research was named the #2 Healthiest Employer by the Triangle Business Journal.

  • Cato Research is a proud member of the BIOCOM CRO Initiative!

    BIOCOM member

Recent Posts

  • May 7, 2012 - New FDA Guidances from April 2012 – Here’s a list of the notable guidances released by FDA in April 2012, compiled by Cato Research Regulatory Scientist Cathy Anderson. [...]

  • May 2, 2012 - Cato Research Canada Celebrates Two Decades of Success in the Drug Development Industry – Over the past 5 years, the life sciences industry throughout Canada, and especially in QuĂ©bec, has been extensively challenged by a lack of available investment capital. Many pharmaceutical and biotechnology companies were forced to make headcount reductions, liquidate assets, and, ultimately, close operations. [...]

  • May 2, 2012 - Across the Board Disqualifications for Clinical Investigators – News has been hitting all over the regulatory blog sites, but in case you haven’t already seen this, the FDA issued a final regulation earlier this week (April 30th) that broadens the rules for clinical investigator disqualifications. Previously, if an investigator (clinical-investigator or sponsor-investigator) was determined to be non-compliant and ineligible to receive clinical trial material such as an investigational drug product, [...]

  • More Posts...